Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dermatologists weigh in: can a tiny dose of acne drug turn back the clock on aging skin?

NCT ID NCT07296536

Knowledge-focused Sponsor: Venus Research Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study asks a panel of 15 experienced dermatologists to share their opinions on using very low doses of isotretinoin (a drug usually used for acne) to improve skin texture, reduce pore size, and slow signs of aging. No patients receive treatment; instead, the goal is to create expert guidelines on who might benefit, how to dose the drug safely, and what monitoring is needed. The results will help doctors make informed decisions about this off-label use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Target panel: 20-35 experienced dermatologists with practical knowledge of isotretinoin use for rejuvenation or acne. Recruitment: Purposive sampling, stratified to ensure diversity in: Practice setting (academic, private, public) Geographic location Years of experience Baseline data collected: Age, sex, region, practice setting, years of experience, isotretinoin prescribing frequency, research or guideline involvement, declared conflicts of interest. Panel retention strategy: Over-recruit by 10-20% to compensate for attrition; maintain anonymity of responses; clear instructions and timelines for participation.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Board-certified dermatologists or equivalent. * 5 years clinical experience in dermatology. Practical experience prescribing isotretinoin, including low- or micro-dose regimens for rejuvenation or acne. Active engagement in clinical dermatology, teaching, research, or guideline development. Willingness to participate in all Delphi rounds and provide informed consent. Exclusion Criteria: * Non-dermatology specialists. Less than 5 years of clinical experience. Lack of relevant isotretinoin experience. Significant undisclosed conflict of interest with isotretinoin manufacturers. Inability to participate in all Delphi rounds.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Isotretinoin are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Isotretinoin Isotretinoin adverse reaction Rejuvenation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Venus Research Center

    Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.